Skip to main content
Premium Trial:

Request an Annual Quote

Oxford Nanopore Licenses IP from Harvard, Collaborators

NEW YORK (GenomeWeb News) – Oxford Nanopore Technologies has acquired the exclusive rights to develop and market some nanopore technologies from Harvard University and collaborators at the University of California Santa Cruz and the National Institute of Standards and Technology, the company said today.

Oxford, UK-based Oxford Nanopore said it has agreed to support nanopore research at Harvard that could help to advance the field.

The technology Oxford Nanopore has licensed includes intellectual property that was developed by Harvard researchers Daniel Branton, George Church, and Jene Golovchenko; University of California Santa Cruz collaborators David Deamer and Mark Akeson; and John Kasianowicz at the National Institute of Standards and Technology.

The technology is complementary to previous research conducted by Oxford Nanopore Co-founder Hagan Bayley. According to the firm, Bayley “pioneered the field of nanopores as sensors of single molecules, with a specific focus on the identification of DNA bases.”

The company said this label-free nanopore technology could help to reduce the cost of DNA sequencing. It also could be useful in many genomics applications, medical diagnostic development and treatments, and other areas such as energy, defense, and agriculture research, said Oxford Nanopore.

Financial terms of the agreement were not released.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.